The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1332
February 22, 2010
View Complete Issue         Table of Contents 2019 
Iloperidone (Fanapt) - Another Second-Generation Antipsychotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Iloperidone (Fanapt) - Another Second-Generation Antipsychotic
February 22, 2010 (Issue: 1332)
The FDA has approved the marketing of iloperidone (Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone (Risperdal, and others).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Iloperidone (Fanapt) - Another Second-Generation Antipsychotic
Article code: 1332a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.